Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
Join the brightest minds in regulatory at the annual Regulatory Convergence. See the global regulatory community in action. Intensive workshops. Topical sessions. Meet ups with regulators. This is where it all comes together.
With so many global regulation changes, staying informed is a challenge. Join other regulatory professionals as you navigate the gray together.
For 20 years, our flagship publication, Fundamentals of US Regulatory Affairs, has been giving regulatory professionals the insights and answers they need, right at their fingertips.
There are hundreds of RAC testing centers available worldwide. Either RAC exam (Devices and Drugs) may be taken at any location. Find an upcoming exam at a location near you.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
The RAPS store will be under maintenance Saturday, 29 February between 6 AM and 12 PM EST. Store functionality may be unavailable at times during this window. We apologize for any inconvenience caused during this time.
Posted 30 December 2011 | By Alexander Gaffney, RAC
The US Food and Drug Administration (FDA) released Friday a new draft guidance titled, Use of Histology in Biomarker Qualification Studies.
The document outlines the processes that industry should use to ensure histology data is accurate, sound, and adheres to scientific standards for biomarker characterization and qualification.
The FDA is hoping to provide clarity to the biomarker development process to spur successful product development, as outlined in its Critical Path Initiative. Biomarkers broadly apply to the molecular structure, biochemical measurements, and organ system functions of the body.
The guidance notes that, "if a biomarker becomes qualified, analytically valid measurements of it can be relied upon to have a specific and interpretable meaning in drug development and regulatory decision-making." This would be mutually beneficial to both the FDA and to industry in speeding up the development time and premarket review of the substance.
The Federal Register posting for the draft guidance also notes that the draft guidance is aimed at reducing the instances of unqualified biomarkers, which "can do considerable harm" to the drug development process by promoting an "erroneous perception of safety" and an inadequate risk-benefit profile that is unlikely to be approved by the FDA.
Tags: Qualification Studies, Histology, Latest News, biomarkers, draft guidance
Regulatory Focus newsletters
All the biggest regulatory news and happenings.